Market Overview

Lower PC Demand Is 'Bad For Intel,' Says Citi

Share:

Citi lowered its estimates on Intel Corporation (NASDAQ: INTC) and cut its price target from $35 to $34. The firm reiterated a Neutral rating on the stock.

Analyst Christopher Danely observed a continued decline in PC demand that could result in shipments coming in below Intel guidance and consensus estimates.

Citi IT Hardware Analyst Jim Suva recently lowered the 2015 PC shipment growth estimate from flat year-over-year to down 2 percent. Furthermore, Danely’s analysis indicated that a 1 percent change in PC demand resulted in 3 percent change in Intel’s EPS.

Due to the expectation for lower PC demand, Danely reduced the 2015 revenue estimate from $57.3 billion to $56.9 billion and the EPS estimate from $2.27 to $2.20. Citi’s new EPS estimate was 7 percent below the consensus of $2.38.

The analysts had previously expected flat PC shipments in 2015 due to emerging market demand. “However, the latest datapoints indicate emerging market PC demand remains soft,” said Danely, which is “bad for Intel.”

Intel recently traded at $33.54, down 1.19 percent.

Latest Ratings for INTC

DateFirmActionFromTo
Aug 2019UpgradesUnderperformMarket Perform
Aug 2019Initiates Coverage OnHold
Jul 2019MaintainsOutperform

View More Analyst Ratings for INTC
View the Latest Analyst Ratings

Posted-In: Christopher Danely Citi Jim SuvaAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (INTC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BKUDA DavidsonInitiates Coverage On39.0
JDVertical GroupInitiates Coverage On
WWells FargoMaintains123.0
TXRHWells FargoMaintains48.0
QSRWells FargoMaintains75.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors

GBP/USD Moves Lower